Low-Dose Transplant Drug Shows Promise in Slowing Type 1 Diabetes Progression
New research suggests that a smaller dose of an inexpensive, long-used immunosuppressant drug can slow the loss of insulin-producing cells in newly diagnosed Type 1 diabetes. The findings could offer a lower-cost option with fewer side effects than previous approaches.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- A low dose of polyclonal antithymocyte globulin (ATG)—a drug used in transplant surgery for decades—showed promise in slowing Type 1 diabetes progression in newly diagnosed patients
- The low dose was nearly as effective as higher doses at preserving remaining insulin-producing beta cells, but with fewer side effects
- The study targeted the 'honeymoon phase,' the window of time after diagnosis when the pancreas still produces some insulin
- Preserving beta cell function during this early phase is linked to reduced risk of long-term diabetes complications like heart and kidney disease
A New Window of Opportunity
Type 1 diabetes develops when the immune system mistakenly attacks the beta cells in the pancreas that produce insulin. Insulin is essential because it allows glucose from the blood to enter cells for energy. Without enough insulin, glucose builds up in the bloodstream.
When Type 1 diabetes is first diagnosed, there's a critical window called the 'honeymoon phase,' during which some beta cells continue to produce insulin. This phase presents an opportunity: if researchers can protect the remaining beta cells during this time, patients may retain more insulin production and face lower risk of serious complications like heart and kidney disease.
What the Study Found
Researchers studied 117 people between ages 5 and 25 who had been diagnosed with Type 1 diabetes within nine weeks of enrolling in the trial. Participants received one of three doses of ATG, a drug that suppresses immune activity and has been safely used in transplant surgeries for many years.
The results suggest that a low dose of ATG was nearly as effective as higher doses at slowing the loss of beta cells—but with fewer unwanted side effects. This finding is significant because it suggests that lower, more affordable doses might be just as beneficial, potentially making the treatment more accessible and easier to tolerate.
Why This Matters
If confirmed in additional studies, a low-dose ATG approach could offer newly diagnosed Type 1 patients a way to extend their honeymoon phase and preserve more of their own insulin production. The cost-effectiveness of using an older, well-established drug is also noteworthy in a field often dominated by expensive newer therapies.
The research adds to growing evidence that intervening early in Type 1 diabetes—targeting that critical window soon after diagnosis—may make a meaningful difference in long-term health outcomes.
Evidence label
Origin: health.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Cure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Cure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Cure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Cure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Cure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Cure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies